Emerging role of engineered exosomes in nonalcoholic fatty liver disease.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD comprises a continuum of liver abnormalities from nonalcoholic fatty liver to nonalcoholic steatohepatitis, and can even lead to cirrhosis and liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes have become an ideal drug delivery tool because of their high transmissibility, low immunogenicity, easy accessibility and targeting. Exosomes with specific modifications, known as engineered exosomes, have the potential to treat a variety of diseases. Here, we review the treatment of NAFLD with engineered exosomes and the potential use of exosomes as biomarkers and therapeutic targets for NAFLD.

• Authors: Jian Ding, Chen Xu, Ming Xu, Xiao-Yue He, Wei-Na Li, Fei He
• Journal: World journal of hepatology (World J Hepatol) Vol. 15 Issue 3 Pg. 386-392 (Mar 27 2023) ISSN: 1948-5182 [Print] United States
• PMID: 37034232 (Publication Type: Journal Article, Review)
• Copyright: ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.